Physician profile
Thomas Feldman
NPI 1366558983
$2,482.48
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,853 · 2020: $420 · 2021: $185 · 2022: $24.61.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $723.27 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $533.74 | 2019-2021 | |
| Abbvie INC. | $305.59 | 2019-2021 | |
| Pfizer INC. | $148.58 | 2019-2020 | |
| Allergan, INC. | $138.30 | 2019-2020 | |
| Janssen Biotech, INC. | $102.65 | 2019-2021 | |
| Celgene Corporation | $75.45 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $73.01 | 2019-2020 | |
| Qol Medical, LLC | $66.06 | 2019 | |
| Ironwood Pharmaceuticals, INC | $58.27 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $44.55 | 2019-2020 | |
| Shire North American Group INC | $43.66 | 2019 | |
| Ucb, INC. | $38.94 | 2019-2020 | |
| Gilead Sciences, INC. | $37.86 | 2019 | |
| Alfasigma USA, INC. | $23.54 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $20.15 | 2019 | |
| Braintree Laboratories, INC. | $19.65 | 2021 | |
| Dova Pharmaceuticals | $16.04 | 2019 | |
| Concordia Pharmaceuticals INC. | $13.17 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.